The 36-month beta value for RANI is at -0.03. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RANI is 26.65M, and currently, shorts hold a 13.64% of that float. The average trading volume for RANI on July 09, 2025 was 454.52K shares.
RANI) stock’s latest price update
Rani Therapeutics Holdings Inc (NASDAQ: RANI)’s stock price has gone rise by 12.14% in comparison to its previous close of $0.54, however, the company has experienced a 17.03% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-19 that – Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets – SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd.
RANI’s Market Performance
RANI’s stock has risen by 17.03% in the past week, with a monthly rise of 13.71% and a quarterly drop of -50.30%. The volatility ratio for the week is 8.55% while the volatility levels for the last 30 days are 7.66% for Rani Therapeutics Holdings Inc The simple moving average for the past 20 days is 12.92% for RANI’s stock, with a -59.42% simple moving average for the past 200 days.
Analysts’ Opinion of RANI
Many brokerage firms have already submitted their reports for RANI stocks, with Oppenheimer repeating the rating for RANI by listing it as a “Outperform.” The predicted price for RANI in the upcoming period, according to Oppenheimer is $17 based on the research report published on August 02, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see RANI reach a price target of $15. The rating they have provided for RANI stocks is “Buy” according to the report published on June 14th, 2024.
Rodman & Renshaw gave a rating of “Buy” to RANI, setting the target price at $10 in the report published on June 13th of the previous year.
RANI Trading at -9.35% from the 50-Day Moving Average
After a stumble in the market that brought RANI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.65% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RANI starting from McKinley Kate, who purchase 17,960 shares at the price of $1.67 back on Dec 13 ’24. After this action, McKinley Kate now owns 17,960 shares of Rani Therapeutics Holdings Inc, valued at $29,993 using the latest closing price.
Imran Talat, the Chief Executive Officer of Rani Therapeutics Holdings Inc, purchase 10,296 shares at $1.94 during a trade that took place back on Dec 09 ’24, which means that Imran Talat is holding 494,751 shares at $19,974 based on the most recent closing price.
Stock Fundamentals for RANI
Current profitability levels for the company are sitting at:
- -49.9 for the present operating margin
- 0.49 for the gross margin
The net margin for Rani Therapeutics Holdings Inc stands at -28.99. The total capital return value is set at -12.84. Equity return is now at value -1372.59, with -76.76 for asset returns.
Based on Rani Therapeutics Holdings Inc (RANI), the company’s capital structure generated 1.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at -6.46. The interest coverage ratio of the stock is -18.36.
Currently, EBITDA for the company is -50.52 million with net debt to EBITDA at -0.2. When we switch over and look at the enterprise to sales, we see a ratio of 43.04. The receivables turnover for the company is 1.71for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.88.
Conclusion
In conclusion, Rani Therapeutics Holdings Inc (RANI) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
